Form 8-K - Current report:
SEC Accession No. 0001104659-24-101176
Filing Date
2024-09-19
Accepted
2024-09-19 07:00:27
Documents
13
Period of Report
2024-09-17
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2424352d2_8k.htm   iXBRL 8-K 30180
  Complete submission text file 0001104659-24-101176.txt   204635

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA btai-20240917.xsd EX-101.SCH 3048
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE btai-20240917_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btai-20240917_pre.xml EX-101.PRE 22381
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2424352d2_8k_htm.xml XML 3567
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

EIN.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38410 | Film No.: 241309069
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)